Yıl: 2020 Cilt: 25 Sayı: 2 Sayfa Aralığı: 111 - 120 Metin Dili: Türkçe DOI: 10.5578/flora.69574 İndeks Tarihi: 17-12-2020

Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum

Öz:
İlk olarak 2019 yılı Aralık ayında, Çin’in Wuhan şehrinde nedeni belirlenemeyen pnömoni olgularının bildirilmesi üzerine yapılan incelemelersonucunda etkenin yeni bir koronavirüs olduğu anlaşılmış, etken SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2)olarak tanımlanmış, hastalık ise COVID-19 (coronavirus disease-2019) olarak adlandırılmıştır. Hastalık başlangıçta zoonotik kabuledilmiş olmakla birlikte, insandan insana bulaş varlığı da gösterilmiş ve temel bulaş yolu haline gelmiş, kısa süre içinde olgu sayılarındabelirgin artış ortaya çıkmış ve hastalık dünya çapında yayılım göstermiştir. Dünya Sağlık Örgütü 11 Mart 2020 tarihinde COVID-19’uküresel bir pandemi olarak ilan etmiştir. COVID-19 tanısı alan kişi sayısının 6 Mayıs 2020 tarihli verilere dayanılarak 3.588.773 olduğu,215 farklı ülke ve bölgeden olgu bildirimleri yapıldığı, hastalık nedeniyle 247.503 kişinin yaşamını yitirdiği rapor edilmiştir. Ülkemizdeise ilk olgu 10 Mart 2020 tarihinde saptanmış, hastalığa bağlı ilk ölüm 17 Mart 2020 tarihinde rapor edilmiş, 6 Mayıs 2020 tarihliverilere göre ülkemizde saptanmış olan toplam olgu sayısı 131.744, hastalığa bağlı ölüm sayısı 3584 olarak bildirilmiştir. SARS-CoV-2’nin biyolojisi, epidemiyolojisi ve oluşturduğu klinik tablonun özellikleri ile ilgili bilgiler her geçen gün artmaktadır. Viral genomun dizianalizinin yapılmış olması tanısal testlerin geliştirilmesine, tedavi ve aşı geliştirme alanındaki çalışmaların başlamasına olanak tanımıştır.Bu derleme yazıda, SARS-CoV-2’nin neden olduğu hastalık tablosu ve epidemiyolojisi, tanı, tedavi ve hastalıktan korunma önlemlerikonusundaki gelişmeler tartışılmıştır.
Anahtar Kelime:

Novel Coronavirus (SARS-CoV-2) Pandemic: Overview and Current Status

Öz:
In the end of December 2019, a novel coronavirus was identified as the cause of pneumonia cases in Wuhan, China. The disease was later named as COVID-19 (coronavirus disease 2019) and the causative agent was designated as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). Even though the disease was suggested to be of zoonotic origin, human to human spread was also described and became the main mode of transmission. The number of cases significantly increased within a short period of time and the disease spread worldwide. On March 11, 2020, the World Health Organization announced COVID-19 outbreak as a pandemic. As of May 6, 2020, it has been reported that there are 3.588.773 people diagnosed with COVID-19 among 215 countries, territories or areas, and 247.503 people have died from the disease. In our country, the first case was identified on March 10, 2020, and the first death from the disease was reported on March 17, 2020. According to the data announced on May 6, 2020, the total number of cases detected in our country was 131.744, and the number of deaths related to the disease was 3584. The knowledge on the characteristics and epidemiology of SARS-CoV-2 and COVID-19 has been increasing day by day. Sequence analysis of the viral genome enabled the development of diagnostic tests and facilitated the initiation of research on both therapeutic options and vaccine development. In this review article, current information on the biology, epidemiology, clinical features, diagnosis, treatment, and prevention of SARS-CoV-2 and COVID-19 was discussed.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. World Health Organization (WHO). Erişim tarihi: 17 Mart 2020. Available from: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019
  • 2. European Centre for Disease Prevention and Control (ECDC). Erişim tarihi: 17 Mart 2020. Available from: https:// www.ecdc.europa.eu/en/factsheet-health-professionals- coronaviruses
  • 3. Türkiye Cumhuriyeti Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Erişim tarihi: 14 Nisan 2020. Available from: https://hsgm.saglik.gov.tr/tr/covid19
  • 4. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020;92:418-23.
  • 5. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;102433.
  • 6. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol 2020;92:401-2.
  • 7. International Committee on Taxonomy of Viruses (ICTV). Erişim tarihi: 17 Mart 2020. Available from: https://talk. ictvonline.org/
  • 8. Del Rio C, Malani PN. COVID-19-new insights on a rapidly changing epidemic. JAMA 2020;Feb 28.
  • 9. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1- 23.
  • 10. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin- converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46:586-90.
  • 11. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-7.
  • 12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506.
  • 13. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med 2020;201:P7-P8.
  • 14. Wu P, Hao X, Lau EHY, Wong JY, Leung KSM, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill 2020;25(3).
  • 15. World Health Organization (WHO). Erişim tarihi: 6 Mayıs 2020. Available from:. https://covid19.who.int
  • 16. Türkiye Cumhuriyeti Sağlık Bakanlığı. Erişim tarihi: 6 Mayıs 2020. Available from: https://covid19.saglik.gov.tr/
  • 17. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;Feb 21.
  • 18. Centers for Disease Control and Prevention (CDC). Available from: https://www.cdc.gov/coronavirus/2019-ncov/ php/risk-assessment.html
  • 19. European Centre for Disease Prevention and Control (ECDC). Erişim tarihi: 25 Mart 2020. Available from: https:// www.ecdc.europa.eu/en/publications-data/resource- estimation-contact-tracing-quarantine-and-monitoring- activities-covid-19
  • 20. UpToDate. Erişim tarihi: 28 Nisan 2020. Available from: https://www.uptodate.com/contents/coronavirus-disease- 2019-covid-19-epidemiology-virology-clinical-features- diagnosis-and-prevention
  • 21. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci 2020;Mar 4.
  • 22. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020;9:386-9.
  • 23. European Centre for Disease Prevention and Control (ECDC). Erişim tarihi: 20 Mart 2020. Available from: https:// www.ecdc.europa.eu/sites/default/files/documents/ COVID-19-Discharge-criteria.pdf
  • 24. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;Feb 7.
  • 25. University of Michigan. Michigan Medicine. Erişim tarihi: 22 Mart 2020. Available from: https://labblog.uofmhealth. org/rounds/how-scientists-quantify-intensity-of-an-outbreak- like-covid-19
  • 26. Ergönül Ö. Enfeksiyon hastalıkları epidemiyolojisi. Hastane Enfeksiyonları: Korunma ve Kontrol Sempozyum Dizisi 2008;60:30-41.
  • 27. Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis 2020;92:214-7.
  • 28. American Academy of Otolaryngology-Head and Neck Surgery. Erişim tarihi: 23 Mart 2020. Available from: https:// www.entnet.org/content/coronavirus-disease-2019-resources
  • 29. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;Feb 24.
  • 30. UpToDate. Erişim tarihi: 5 Mayıs 2020. Available from: https://www.uptodate.com/contents/coronavirus-disease- 2019-covid-19-hypercoagulability
  • 31. Cui Y, Tian M, Huang D, Wang X, Huang Y, Fan L, et al. A 55-day-old female infant infected with COVID 19: presenting with pneumonia, liver injury, and heart damage. J Infect Dis 2020;Mar 17.
  • 32. Korea Centers for Disease Control and Prevention (KCDC). Erişim tarihi: 14 Mart 2020. Available from: https:// www.cdc.go.kr/board/board.es?mid=a30402000000&- bid=0030
  • 33. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barre syndrome associated with SARS-CoV-2. N Engl J Med 2020;Apr 17.
  • 34. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
  • 35. Centers for Disease Control and Prevention (CDC). Erişim tarihi: 17 Mart 2020. Available from: https://www.cdc. gov/coronavirus/2019-nCoV/lab/index.html
  • 36. Centers for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19). Erişim tarihi: 15 Mart 2020. Available from: https://www. cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical- specimens.html
  • 37. UpToDate. Erişim tarihi: 5 Mayıs 2020. Available from: https://www.uptodate.com/contents/coronavirus-disease- 2019-covid-19-management-in-hospitalized-adults
  • 38. National Institute of Health Clinical Trials. Erişim tarihi: 28 Nisan 2020. Available from: https://clinicaltrials.gov/ct2/ results?cond=covid-19
  • 39. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269.
  • 40. US Food and Drug Administration (US FDA). Remdesivir letter of EUA. Erişim tarihi: 6 Mayıs 2020. Available at: https:// www.fda.gov/media/137564/download
  • 41. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004;323:264-8.
  • 42. US Food and Drug Administration (US FDA). Erişim tarihi: 6 Mayıs 2020. Available at: https://www.fda.gov/media/ 136534/download
  • 43. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical triaI. Int J Antimicrob Agents 2020;Mar 20:105949.
  • 44. American Association for the Advancement of Science (AAAS). Erişim tarihi: 5 Mayıs 2020. Available at: https:// www.sciencemag.org/news/2020/03/who-launches-global- megatrial-four-most-promising-coronavirus-treatments#
  • 45. National Institute of Health. Erişim tarihi: 21 Nisan 2020. Available from: https://www.covid19treatmentguidelines. nih.gov/therapeutic-options-under-investigation/
APA Alp S, Unal S (2020). Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum. , 111 - 120. 10.5578/flora.69574
Chicago Alp Sehnaz,Unal Serhat Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum. (2020): 111 - 120. 10.5578/flora.69574
MLA Alp Sehnaz,Unal Serhat Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum. , 2020, ss.111 - 120. 10.5578/flora.69574
AMA Alp S,Unal S Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum. . 2020; 111 - 120. 10.5578/flora.69574
Vancouver Alp S,Unal S Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum. . 2020; 111 - 120. 10.5578/flora.69574
IEEE Alp S,Unal S "Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum." , ss.111 - 120, 2020. 10.5578/flora.69574
ISNAD Alp, Sehnaz - Unal, Serhat. "Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum". (2020), 111-120. https://doi.org/10.5578/flora.69574
APA Alp S, Unal S (2020). Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 25(2), 111 - 120. 10.5578/flora.69574
Chicago Alp Sehnaz,Unal Serhat Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 25, no.2 (2020): 111 - 120. 10.5578/flora.69574
MLA Alp Sehnaz,Unal Serhat Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, vol.25, no.2, 2020, ss.111 - 120. 10.5578/flora.69574
AMA Alp S,Unal S Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2020; 25(2): 111 - 120. 10.5578/flora.69574
Vancouver Alp S,Unal S Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2020; 25(2): 111 - 120. 10.5578/flora.69574
IEEE Alp S,Unal S "Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum." Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 25, ss.111 - 120, 2020. 10.5578/flora.69574
ISNAD Alp, Sehnaz - Unal, Serhat. "Yeni Koronavirüs (SARS-CoV-2) Kaynaklı Pandemi: Gelişmeler ve Güncel Durum". Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 25/2 (2020), 111-120. https://doi.org/10.5578/flora.69574